Merck 1Q 2024 sales up 9% to US$ 15.8 billion

Sales reflect continued strong growth in oncology and vaccines

New chemical method could cut waste from drug production

One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development

Voydeya approved in the EU as add-on treatment to ravulizumab

ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue

Mac-Chem Products (India)’s Boisar facility renews EU-GMP certification

Biocon inks agreement for Ozempic commercialization in Brazil with Biomm

Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market

Briefs: Sun Pharma and Kimia Biosciences

Sun Pharma's Dadra facility receives OAI status from US FDA

SPARC announces results from planned interim analysis of PROSEEK Study

USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial

EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia

MTD acquires Ypsomed's pen needle and BGM businesses

This acquisition enables MTD to open new, strategic markets